The Series C financing was led by Elevage Medical Technologies with backing from Patient Square Capital and other investors.
"This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come."
The investment was led by the BOKA Group to fund the commercial launch of the firm's first-generation terminal.
"All of our investors’ confidence reflects the critical role our technology plays in addressing the growing demand for resilient and seamless connectivity across defence and space industries. We are laser-focused on executing our strategy and delivering the cutting-edge solutions our partners and customers rely on, ensuring critical communications in the most challenging environments."
Optiver led the financing round with participation from FactSet, Nasdaq Ventures, IQ Capital and CTC Venture Capital.
"We are thrilled to welcome Optiver as a significant shareholder and are delighted to have the ongoing support from our existing investors who have backed the latest round. We have an incredibly diverse team of supporting investors, with deep-seated global market and technology expertise, and we are poised to scale the business further, as we build out and scale our data feed business and futures coverage and wider product offering globally."
The Series C round was led by Planet First Partners to support scaling and technological roadmaps.
"Quantum error correction is the critical enabler for the industry’s next huge wave of progress, from today’s small error-prone machines to large and reliable quantum computers that will start a new age of human progress as significant as the digital revolution."
